Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ARE SMAD2, SMAD3 AND TGF-β GENE EXPRESSION VALUABLE IN THE MANAGEMENT OF THE URGE URINARY INCONTINENCE?

NCT04525105 is registered in ClinicalTrials.gov with Muğla Sıtkı Koçman University as lead sponsor.

NCT NCT04525105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04525105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ARE SMAD2, SMAD3 AND TGF-β GENE EXPRESSION VALUABLE IN THE MANAGEMENT OF THE URGE URINARY INCONTINENCE?
Lead sponsor
Muğla Sıtkı Koçman University
Phase
Observational
Overall status
Completed
Start date
November 1, 2017
Completion date
January 1, 2020
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pelvic organ prolapse, smad2, smad3, tgf-β, urge urinary incontinence